美国食品和药物管理局批准了诺沃诺迪斯克口服的Wegovy药丸治疗肥胖症, 推出于2026年1月, 平均体重减轻13.6%. The FDA approved Novo Nordisk’s oral Wegovy pill for obesity, launching in January 2026 with 13.6% average weight loss.

美国食品和药物管理局批准了诺沃诺迪斯克口服版的Wegovy,这是第一种含有西马格卢的基于药丸的治疗肥胖症. The FDA has approved Novo Nordisk’s oral version of Wegovy, the first pill-based treatment for obesity, containing semaglutide. 它将于2026年1月初启动,通过零售药店、在线平台和远程保健提供商直接向美国付现金的病人提供。 It will launch in early January 2026, available directly to U.S. cash-paying patients through retail pharmacies, online platforms, and telehealth providers. 该药片每天在空腹中服用一次,在吃晚饭前等待30分钟,试验中体重平均下降13.6%,与注射形式相仿。 The pill, taken once daily on an empty stomach with a 30-minute wait before eating, showed average 13.6% body weight loss in trials—comparable to the injectable form. 一些供应商每月价格为149美元,其目的是改善因针头恐惧症或费用问题避免注射者获得注射服务的机会。 Priced at $149 per month for some providers, it aims to improve access for those avoiding injections due to needle phobia or cost. Eli Lilly的口服药仍在审查中。 The move comes amid competition with Eli Lilly’s oral drug, which is still under review.